All In Biotech

Drug Trial Radar · NCT06217952

Safety, Tolerability, and Pharmacokinetics of SPL84 in Healthy Volunteers

A Phase 1, Randomized, Placebo-Controlled, Double Blind Single Ascending Dose Study in Healthy Volunteers to Evaluate the Safety, Tolerability, and Pharmacokinetics of SPL84

Last checked: Nov 19, 2026Latest source record: Jan 23, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

32

Actual

Start

Feb 5, 2023

Primary completion

Aug 6, 2023

Study completion Aug 6, 2023

Sponsor

Lead sponsor
SpliSense Ltd.Industry
Sponsor type
Industry
First posted
Jan 23, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Sequential
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This Phase 1 study evaluated the safety, tolerability, and pharmacokinetics of SPL84 single ascending doses (SAD) in healthy volunteers (HV)

Conditions

  • Cystic Fibrosis

Interventions

  • SPL84Drug

    SPL84 solution for nebulization

  • PlaceboOther

    Placebo solution for nebulization

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety and Tolerability of SPL84 as evaluated by number of subjects with at least one treatment-related adverse event (AE) or serious adverse event (SAEs)Time frame: Day 1 through Day 31
  2. Safety and Tolerability of SPL84 as assessed by number of participants with abnormal heart rateTime frame: Day 1 through Day 31
  3. Safety and Tolerability of SPL84 as assessed by number of participants with abnormal respiratory rateTime frame: Day 1 through Day 31
  4. Safety and Tolerability of SPL84 as assessed by number of participants with abnormal systolic and diastolic blood pressureTime frame: Day 1 through Day 31
  5. Safety and Tolerability of SPL84 as assessed by number of participants with abnormal oximetryTime frame: Day 1 through Day 31
  6. Safety and Tolerability of SPL84 as assessed by number of participants with abnormal temperatureTime frame: Day 1 through Day 31
  7. Safety and Tolerability of SPL84 as assessed by number of participants with abnormal hematology lab test resultsTime frame: Day 1 through Day 31
  8. Safety and Tolerability of SPL84 as assessed by number of participants with abnormal biochemistry lab test resultsTime frame: Day 1 through Day 31
  9. Safety and Tolerability of SPL84 as assessed by number of participants with abnormal urinalysis lab test resultsTime frame: Day 1 through Day 31
  10. Safety and Tolerability of SPL84 as assessed by number of participants with abnormal electrocardiogram (ECG) parametersTime frame: Day 1 through Day 31
  11. Safety and Tolerability of SPL84 as assessed by number of participants with abnormal physical examination findingsTime frame: Day 1 through Day 31
  12. Safety and Tolerability of SPL84 as assessed by number of participants with abnormal Pulmonary function tests resultsTime frame: Day 1 through Day 31

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Hadassah Ein Kerem Hospital Clinical Research Center

    Jerusalem, Israel

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.